[62] This was followed by the development of semaglutide by a team of researchers at Novo Nordisk, including Jesper Lau, Thomas Kruse, and Paw Bloch
(Please note this applies only for weekly injections such as Ozempic, not other forms of GLP-1s.) Kristina D
The researchers found that the risk for a primary outcome event (major kidney disease events, a composite of the onset of kidney failure, at least a 50 percent reduction in the estimated glomerular filtration rate from baseline, or death from kidney-related or cardiovascular causes) was significantly lower in the semaglutide group (331 versus 410 first events
If you are currently on a stable dose Continue your medication as prescribed
Nurse understanding of the drug risks and impact of shortages aids patient safety
Using products that contain ingredients like hyaluronic acid, retinoids, and peptides can help support your skins structure and appearance